NYSE:ABT • US0028241000
The current stock price of ABT is 111.47 USD. In the past month the price decreased by -10.82%. In the past year, price decreased by -14.65%.
ChartMill assigns a fundamental rating of 6 / 10 to ABT. ABT has an excellent profitability rating, but there are some minor concerns on its financial health.
Over the last trailing twelve months ABT reported a non-GAAP Earnings per Share(EPS) of 5.15. The EPS increased by 10.28% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 31.88% | ||
| ROA | 16.6% | ||
| ROE | 27.43% | ||
| Debt/Equity | 0.23 |
35 analysts have analysed ABT and the average price target is 136.02 USD. This implies a price increase of 22.03% is expected in the next year compared to the current price of 111.47.
For the next year, analysts expect an EPS growth of 11.5% and a revenue growth 7% for ABT
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ISRG | INTUITIVE SURGICAL INC | 46.82 | 175.875B | ||
| SYK | STRYKER CORP | 24.2 | 139.086B | ||
| BSX | BOSTON SCIENTIFIC CORP | 21.16 | 108.957B | ||
| IDXX | IDEXX LABORATORIES INC | 41.66 | 51.801B | ||
| BDX | BECTON DICKINSON AND CO | 11.28 | 51.46B | ||
| EW | EDWARDS LIFESCIENCES CORP | 25.71 | 46.035B | ||
| RMD | RESMED INC | 20.01 | 37.897B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 15.66 | 36.095B | ||
| DXCM | DEXCOM INC | 25.78 | 26.58B |
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the New York Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
Abbott Laboratories engages in the discovery, development, manufacture, and sale of healthcare products. The company is headquartered in Abbott Park, Illinois. The Company’s principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. Its segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. Diagnostic Products segment is involved in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. Nutritional Products segment is engaged in the worldwide sales of a broad line of adult and pediatric nutritional products. Medical Devices segment is involved in the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. The company serves people in more than 160 countries.
ABBOTT LABORATORIES
100 Abbott Park Road, Abbot Park
ABBOTT PARK ILLINOIS 60064 US
CEO: Robert B. Ford
Employees: 114000
Phone: 12246676100
Abbott Laboratories engages in the discovery, development, manufacture, and sale of healthcare products. The company is headquartered in Abbott Park, Illinois. The Company’s principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. Its segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. Diagnostic Products segment is involved in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. Nutritional Products segment is engaged in the worldwide sales of a broad line of adult and pediatric nutritional products. Medical Devices segment is involved in the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. The company serves people in more than 160 countries.
The current stock price of ABT is 111.47 USD. The price decreased by -1.87% in the last trading session.
ABBOTT LABORATORIES (ABT) has a dividend yield of 2.31%. The yearly dividend amount is currently 2.21.
ABT has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
ABT stock is listed on the New York Stock Exchange exchange.
35 analysts have analysed ABT and the average price target is 136.02 USD. This implies a price increase of 22.03% is expected in the next year compared to the current price of 111.47.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ABT.